De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bonesupport Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Bonesupport Holding heeft een totaal eigen vermogen van SEK629.4M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK752.6M en SEK123.2M. De EBIT Bonesupport Holding is SEK74.9M waardoor de rentedekking -65.5 is. Het heeft contanten en kortetermijnbeleggingen van SEK114.6M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	-65.5x
Contant	SEK 114.58m
Aandelen	SEK 629.41m
Totaal verplichtingen	SEK 123.21m
Totaal activa	SEK 752.62m

Recente financiële gezondheidsupdates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Recent updates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Insider Buying: The Bonesupport Holding AB (publ) (STO:BONEX) Chief Executive Officer Just Bought 4.0% More Shares

Mar 04

One Bonesupport Holding AB (publ) (STO:BONEX) Analyst Just Cut Their EPS Forecasts

Mar 02

What Kind Of Investors Own Most Of Bonesupport Holding AB (publ) (STO:BONEX)?

Feb 28

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK477.6M ) BONEX } overtreffen de korte termijn passiva ( SEK113.8M ).

Langlopende schulden: De kortetermijnactiva BONEX ( SEK477.6M ) overtreffen de langetermijnschulden ( SEK9.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BONEX is schuldenvrij.

Schuld verminderen: BONEX had 5 jaar geleden geen schulden.

Schuldendekking: BONEX heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: BONEX heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Bonesupport Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Recent updates

Now 22% undervalued

Price target increased by 8.6% to kr323

Consensus EPS estimates fall by 12%, revenue upgraded

Chief Executive Officer recently sold kr18m worth of stock

Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023)

Consensus EPS estimates fall by 14%

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock

Chairman of the board recently bought kr1.6m worth of stock

Second quarter 2021 earnings released

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023